Filing Details
Stoke Therapeutics, Inc. (NASDAQ:STOK) filed a Form 8-K with the Securities and Exchange Commission on June 30, 2026, disclosing a material event.
8k filedNASDAQ:STOK
Stoke Therapeutics, Inc. (STOK) Reports Material Event to SEC
Filing Details Stoke Therapeutics, Inc. (NASDAQ:STOK) filed a Form 8-K with the Securities and Exchange Commission on June 30, 2026, disclosing a material event. Market Context…
Market Context
Stoke Therapeutics, Inc.'s stock currently trades at $32.72 with a market capitalization of $1.9B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Stoke Therapeutics, Inc.'s stock.
All SEC filings for Stoke Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View STOK Stock Page
Frequently Asked Questions
Where can I read STOK's SEC filings?
Browse all filings on our STOK SEC filings page.
What types of SEC filings does Stoke Therapeutics, Inc. file?
Public companies like Stoke Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.